ReviewGastroenterology report2022
Biologics: how far can they go in Crohn's disease?
Review in Gastroenterology report, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Coping Strategies and Experiences of Patients With Crohn's Disease During the COVID-19 Epidemic: A Descriptive Phenomenology Study.Nursing open · 2026Article
- Review
- Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab.Advances in therapy · 2024Article
- Epidemiological investigation of different types of Crohn's disease patients undergoing first abdominal surgery in the era of biological agents: a population-based cohort study.International journal of colorectal disease · 2024Article
- Influential factors on disease activity in Crohn's disease and their Roc curve evaluation: a cross-sectional study.BMC gastroenterology · 2024Article
- Treat to target in Crohn's disease: A practical guide for clinicians.World journal of gastroenterology · 2024Review
- HLA-DQA1*05 correlates with increased risk of anti-drug antibody development and reduced response to infliximab in Chinese patients with Crohn's disease.Gastroenterology report · 2024Article
- Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort study.EClinicalMedicine · 2023Article
- Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn's Disease: A Retrospective Real-World Analysis.Journal of clinical medicine · 2023Article
- Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease.Frontiers in medicine · 2023Article
- Evolving treatment strategies in Crohn's disease.Gastroenterology report · 2023Article
- Intensity-specific considerations for exercise for patients with inflammatory bowel disease.Gastroenterology report · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn's disease and examines the positioning of medical therapy as emerging biologics break onto the market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.